Hana Biosciences, Inc. (NASDAQ: HNAB), a South San Francisco, CA-based biopharmaceutical company, is focused on the acquisition, development and commercialization of novel products to strengthen the foundation of cancer care. The company is dedicated to creating value by accelerating the development of lead product candidates, building a best-in-class team, expanding its pipeline, and nurturing a unique company culture. For further information, visit the Company’s web site at www.hanabiosciences.com.
- 17 years ago
QualityStocks
Hana Biosciences, Inc. (NASDAQ: HNAB)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Issues Investor Update Highlighting Accelerated Revenue Growth, Global Partnerships, and Platform Expansion
Datavault AI (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today…
-
QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of…
-
QualityStocksNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) to Host Webcast and Investor Q&A Following Q3 2025 Financial Results
Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company focused on performance-driven innovation, today announced…